SCOPUS 정보 검색 플랫폼

Lancet Oncology

Volumn 3, Issue 8, 2002, Pages 459-460

Erythropoietin improves quality of life

(3) Littlewood, Timothy J a Cella, David a Nortier, Johan WR a

a JOHN RADCLIFFE HOSPITAL (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEALTH STATUS; HUMAN; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RATING SCALE; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS;

EID: 0036339809 PISSN: 14702045 EISSN: None Source Type: Journal
DOI: 10.1016/S1470-2045(02)00827-6 Document Type: Letter

Times cited : (19)

References (11)

1
- 0036521691
- Human recombinant erythropoietin and quality of life: A wonder drug or something to wonder about?
- (2002) Lancet Oncol , vol.3 , pp. 145-153
- Bottomley, A.¹ Thomas, R.² van Steen, K.³

2
- 0035367087
- Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial
- For the Epoetin Alfa Study Group
- (2001) J. Clin. Oncol , vol.19 , pp. 2865-2874
- Littlewood, T.J.¹ Bajetta, E.² Nortier, J.W.R.³

3
- 0031044609
- Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice
- For the Procrit Study Group
- (1997) J. Clin. Oncol , vol.15 , pp. 1218-1234
- Glaspy, J.¹ Bukowski, R.² Steinberg, D.³

4
- 0031785826
- Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
- For the Procrit Study Group
- (1998) J. Clin. Oncol , vol.16 , pp. 3412-3425
- Demetri, G.D.¹ Kris, M.² Wade, J.³

5
- 0035366382
- Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing
- (2001) J. Clin. Oncol , vol.19 , pp. 2875-2882
- Gabrilove, J.L.¹ Cleeland, C.S.² Livingston, R.B.³

6
- 0000568683
- Cross-language validation of the Functional Assessment of Cancer Therapy-Anemia (FACT-AN) questionnaire
- ECCO 10 Programme (abstr 1457)
- (1999) , vol.35 , pp. S359
- Chang, C.¹ Bresnahan, B.² Gagnon, D.³

7
- 0001635776
- Positive epoetin alfa benefit on quality of life in anemic cancer patients receiving chemotherapy: Results from a randomized placebo-controlled trial
- ECCO 10 Programme (abstr 1461)
- (1999) , vol.35 , pp. S360
- Fallowfield, L.¹ Gagnon, D.² Zagari, M.³

8
- 85001799009
- The significance of missing data in clinical trials
- (2000) Qual Life Res , vol.9 , pp. 275
- Fairclough, D.¹ Gagnon, D.²

9
- 0000367674
- Clinical significance of changes in health-related quality of life (HRQOL) in anemic cancer patients
- (abstr 683P)
- (2000) Ann. Oncol , vol.11 , pp. 149
- Patrick, D.L.¹ Zagari, M.² Gagnon, D.³

10
- 0036964529
- Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales
- in press
- (2002) J. Pain Symptom Manage
- Cella, D.¹ Eton, D.T.² Lai, J.-S.³

11
- 0000105865
- Epoetin alfa overcomes much of the QOL deficit seen in anemic cancer patients
- (abstr 1307)
- (2001) Eur. J. Cancer , vol.37 , pp. S351
- Nortier, J.W.R.¹ Zagari, M.² Vandoros, C.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.